News articles about Vericel (NASDAQ:VCEL) have trended somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Vericel earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.1262569517366 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media stories that may have effected Accern Sentiment’s analysis:

Shares of Vericel (NASDAQ:VCEL) opened at $4.73 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.22 and a current ratio of 2.50. Vericel has a 52-week low of $2.25 and a 52-week high of $6.30.

Vericel (NASDAQ:VCEL) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01. The firm had revenue of $14.26 million for the quarter. Vericel had a negative net margin of 45.11% and a negative return on equity of 265.45%. research analysts forecast that Vericel will post -0.6 EPS for the current year.

A number of brokerages recently weighed in on VCEL. BTIG Research set a $6.00 price target on shares of Vericel and gave the company a “buy” rating in a research report on Monday, October 2nd. ValuEngine downgraded shares of Vericel from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.

WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/10/vericel-vcel-earning-somewhat-favorable-media-coverage-analysis-shows.html.

Vericel Company Profile

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Insider Buying and Selling by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Stock Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related stocks with our FREE daily email newsletter.